

The Applicants have reviewed the application as requested and have noted several additional errors. Certain of the corrections noted below are entered here to amend corrections incorrectly made in the margins of the original filing. The following amendments to the specification are believed to correspond to those requested by the Examiner and not to add new matter to the application:

p. 8, line 19:       ~~--know--~~ should be ~~--known--~~;

p. 9, line 15:       ~~--Vector--~~ should be ~~--Vector<sup>b</sup>--~~;

p. 9, line 15:       ~~--Promoter--~~ should be ~~--Promoter<sup>c</sup>--~~;

p. 10, line 24:       ~~--thiophosphate--~~ should be ~~--phosphate--~~ (one of the products of degradation of the commercial product parathion is thiophosphate, however the parathion oxygen analog, paraoxon, which is used in most analytical testing generates phosphate, not thiophosphate);

p. 16, line 31:       ~~--"co-formulate--~~ should be ~~--"co-formulate"--~~;

p. 17, line 30:       ~~--inactivated--~~ should be ~~--inhibited--~~ (while "inactivate" is a term which would adequately describe the desired effect, "inhibit" is the more descriptive term);

p. 17, line 32:       ~~--inactivation--~~ should be ~~--inhibition--~~;

p. 19, line 23:       ~~--trangenic--~~ should be ~~--transgenic--~~;

p. 23, line 23:       ~~--alliquots--~~ should be ~~--aliquots--~~;

p. 24, line 10:       ~~--HB 101-442--~~ should be ~~--HB101-442--~~;

p. 24, line 24:       ~~--opd--~~ should be ~~--opd--~~;

p. 29, line 13:       ~~--triethanolamine--~~       should be       ~~--triethanolamine--~~;

p. 29, line 14:       ~~--lnCl<sub>2</sub>--~~ should be ~~ZnCl<sub>2</sub>--~~;

p. 35, line 13:       ~~--PTE--~~ should be ~~--OPA--~~ (the enzyme which is the subject of this disclosure has been variously called phosphotriesterase, PTE, and organophosphorus anhydrase, OPA, among others, and in order to remain consistent with the

usag throughout the remainder of the  
disclosur , OPA should be used here as well);

p. 35, line 26: --PTE-- should be --OPA--;

p. 39, line 6: --2000 ±XX µg-- should be --approximately 2000  
µg--;

p. 39, line 8: --9 ±XX µg-- should be --approximately 9 µg--;

p. 40, line 12: -- opd- -- should be -- opd- --;

p. 41, line 33: -- opd- -- should be -- opd- --;

p. 41, line 35: -- opd+ -- should be -- opd+ --;

p. 44, Table 6, line 26: --ZnCl<sub>2</sub>-- should be --ZnCl<sub>2</sub>--;

p. 44, Table 6, line 26: --Mncl<sub>2</sub>-- should be --MnCl<sub>2</sub>--.

p. 47, line 11: --Scores-- should be --Scopes--; and,

p. 47, line 12: -- 1539-1544 -- should be -- 1539-1541 --.

It is requested that the amendments to the specification noted above be entered into the case.

The Examiner also has required the cancellation of the alterations made in the originally filed specification which were initialed by one of the inventors but not dated. It was believed by the Applicants at the time of filing that initialing the non-substantive alterations was adequate to make the changes in the case. However, it is apparent that alterations cannot be made in such a manner and these alterations are requested to be cancelled according to the Examiner's requirements. The cancellation of these alterations is not believed to alter in any substantial manner the content or matter in the specification. Amendments corresponding to the originally initialed but undated alterations have been made above.

The Examiner has also noted that use is made in the application of trademarks which are not capitalized nor accompanied by generic terminology. The Examiner suggests that the specification should be reviewed and corrected for such improperly used descriptions of pesticide products. In particular, the Examiner brought to the